Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias.

Tibes, R; McDonagh, K T; Lekakis, L; Bogenberger, J M; Kim, S; Frazer, N; Mohrland, S; Bassett, D; Garcia, R; Schroeder, K; Shanmugam, V; Carpten, J; Hagelstrom, R T; Beaudry, C; Von Hoff, D; Shea, T C

Tibes, R; McDonagh, K T; Lekakis, L; Bogenberger, J M; Kim, S; Frazer, N; Mohrland, S; Bassett, D; Garcia, R; Schroeder, K; Shanmugam, V; Carpten, J; Hagelstrom, R T; Beaudry, C; Von Hoff, D; Shea, T C.

Affiliation

Tibes R; Division of Hematology & Medical Oncology, Mayo Clinic, 13400 E. Shea Boulevard, Scottsdale, AZ, 85259, USA, tibes.raoul@mayo.edu.

Invest New Drugs ; 33(2): 389-96, 2015 Apr.

Article in En | MEDLINE | ID: mdl-25523151

Subject(s)

Antineoplastic Agents/pharmacokinetics; CDC2 Protein Kinase/antagonists & inhibitors; Leukemia/drug therapy; Masoprocol/analogs & derivatives; Adult; Aged; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/adverse effects; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Liver Function Tests; Male; Masoprocol/administration & dosage; Masoprocol/adverse effects; Masoprocol/pharmacokinetics; Maximum Tolerated Dose; Middle Aged; Polyethylene Glycols/chemistry; Remission Induction

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Masoprocol / Leukemia / CDC2 Protein Kinase / Antineoplastic Agents Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2015 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google